Bavarian Nordic acquires travel vaccines from Emergent BioSolutions: expanding US footprint and manufacturing capacity in plan to become ‘one of the largest pure-play vaccine companies’ 16-Feb-2023 By Rachel Arthur Bavarian Nordic will acquire two travel vaccines – typhoid fever vaccine Vivotif and cholera vaccine Vaxchora - alongside a Phase 3 Chikungunya vaccine candidate: as well as facilities in the US and Switzerland.